Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy

Journal of Viral Hepatitis

Volumn 22, Issue 11, 2015, Pages 871-881

  Hedskog, Charlotte ^a   Dvory Sobol, H ^a   Gontcharova, V ^a   Martin, R ^a   Ouyang, W ^a   Han, B ^a   Gane, E J ^b   Brainard, D ^a   Hyland, R H ^a   Miller, M D ^a   Mo, H ^a   Svarovskaia, E ^a  

^a GILEAD SCIENCES   (United States)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

drug resistance; evolution; S282T; sofosbuvir

Indexed keywords

RIBAVIRIN; SOFOSBUVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN; VIRUS RNA;

ARTICLE; BLOOD SAMPLING; CASE REPORT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; NS5B GENE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION; VIRAL GENETICS; VIRUS GENE; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS STRAIN; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; MISSENSE MUTATION; MOLECULAR EVOLUTION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PHYLOGENY; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LONGITUDINAL STUDIES; MUTATION, MISSENSE; PHYLOGENY; RECURRENCE; RNA, VIRAL; SOFOSBUVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84943815570     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12405     Document Type: Article

References (31)

1. Lam AM, Murakami E, Espiritu C, et al,. PSI-7851, a pronucleotide of beta-D-2′-deoxy-2′-fluoro-2′-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother 2010; 54 (8): 3187-3196.
2. Sofia MJ, Bao D, Chang W, et al,. Discovery of a beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus. J Med Chem 2010; 53 (19): 7202-7218.
3. Rodriguez-Torres M, Lawitz E, Kowdley KV, et al,. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol 2013; 58 (4): 663-668.
4. Osinusi A, Meissner EG, Lee YJ, et al,. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA 2013; 310 (8): 804-811.
5. Kowdley KV, Lawitz E, Crespo I, et al,. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381 (9883): 2100-2107.
6. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368 (20): 1878-1887.
7. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368 (20): 1867-1877.
8. Lam AM, Espiritu C, Bansal S, et al,. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 2012; 56 (6): 3359-3368.
9. Powdrill MH, Tchesnokov EP, Kozak RA, et al,. Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A 2011; 108 (51): 20509-20513.
10. Martell M, Esteban JI, Quer J, et al,. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66 (5): 3225-3229.
11. Duarte EA, Novella IS, Weaver SC, et al,. RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis 1994; 3 (4): 201-214.
12. Svarovskaia ES, Martin R, McHutchison JG, Miller MD, Mo H,. Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy. J Clin Microbiol 2012; 50 (10): 3267-3274.
13. Pawlotsky JM,. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53 (5): 1742-1751.
14. Robinson M, Tian Y, Delaney WET, Greenstein AE,. Preexisting drug-resistance mutations reveal unique barriers to resistance for distinct antivirals. Proc Natl Acad Sci U S A 2011; 108 (25): 10290-10295.
15. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368 (1): 34-44.
16. Gray RR, Parker J, Lemey P, Salemi M, Katzourakis A, Pybus OG,. The mode and tempo of hepatitis C virus evolution within and among hosts. BMC Evol Biol 2011; 11: 131.
17. Zwickl DJ,. Genetic algorithm approaches for the phylogenetic analysis of large biological sequence datasets under the maximum likelihood criterion. Ph.D. dissertation, The University of Texas at Austin. 2006.
18. Sun SC, Bae A, Qi X, et al,. Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates. J Viral Hepat 2011; 18 (12): 861-870.
19. Han D, Strommen K, Anton E, et al,. Analytical validation of an HCV replicon-based phenotypic assay for evaluating replication capacity and susceptibility of genotype 1a/1b patient viruses to polymerase inhibitors. Antivir Ther 2011; 16 (Suppl. 1): A92.
20. Le Pogam S, Seshaadri A, Kosaka A, et al,. Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients. J Antimicrob Chemother 2008; 61 (6): 1205-1216.
21. Verbinnen T, Jacobs T, Vijgen L, et al,. Replication capacity of minority variants in viral populations can affect the assessment of resistance in HCV chimeric replicon phenotyping assays. J Antimicrob Chemother 2012; 67 (10): 2327-37.
22. Sheaffer AK, Lee MS, Hernandez D, et al,. Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates. Antivir Ther 2011; 16 (5): 705-718.
23. Qi X, Bae A, Liu S, et al,. Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates. Antiviral Res 2009; 81 (2): 166-173.
24. Gane EJ, Stedman CA, Hyland RH, et al,. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A Inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146 (3): 736-743.
25. Le Pogam S, Seshaadri A, Ewing A, et al,. RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. J Infect Dis 2010; 202 (10): 1510-1519.
26. Kuntzen T, Timm J, Berical A, et al,. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 2008; 48 (6): 1769-1778.
27. McCown MF, Rajyaguru S, Le Pogam S, et al,. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52 (5): 1604-1612.
28. Lawitz E, Poordad FF, Pang PS, et al,. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383 (9916): 515-523.
29. Lawitz EMH, Doehle B, Pang P, et al,. Once-Daily Sofosbuvir/Ledipasvir Fixed-Dose Combination Is Highly Effective in Subjects With Baseline NS5A Inhibitor and NS3 Protease Inhibitor Resistance-Associated Variants: The LONESTAR Trial. Paper presented at: 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013, 2013; Washington, DC.
30. Han BMH, Wong KA,. In Vitro Analyses of Hepatitis C Virus NS5B S282T Mutants in Multiple HCV Genotypes Show Low Levels of Reduced Susceptibility to Sofosbuvir (GS-7977), No Cross Resistance to Other Classes of Direct-Acting Antivirals, and Hypersensitivity to Ribavirin Paper presented at: 63th Annual Meeting of the American Association for the Study of Liver Diseases; Nov 9-13 2012, 2012; Boston.
31. Tong X, Li L, Haines K, Najera I,. Identification of the NS5B S282T resistant variant and two novel amino acid substitutions that affect replication capacity in hepatitis C virus-infected patients treated with mericitabine and danoprevir. Antimicrob Agents Chemother 2014; 58 (6): 3105-3114.